Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krein, S. L.
Right arrow Articles by Kerr, E. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krein, S. L.
Right arrow Articles by Kerr, E. A.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 25:965-970, 2002
© 2002 by the American Diabetes Association, Inc.


Clinical Care/Education/Nutrition
Original Article

Aspirin Use and Counseling About Aspirin Among Patients With Diabetes

Sarah L. Krein, PHD, RN1,2,3, Sandeep Vijan, MD, MS1,2,3, Leonard M. Pogach, MD, MBA4,5, Mary M. Hogan, PHD, RN1 and Eve A. Kerr, MD, MPH1,2

1 Department of Veterans Affairs’ Center for Practice Management and Outcomes Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan
2 Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
3 Michigan Diabetes Research and Training Center, Ann Arbor, Michigan
4 VA New Jersey Healthcare System, East Orange, New Jersey
5 University of Medicine and Dentistry of New Jersey, Newark, New Jersey

OBJECTIVE—Despite being a safe, effective therapy for lowering cardiovascular risk, only 20% of diabetic patients were using aspirin in the early 1990s. This study examines current physician practices and the use of aspirin therapy by individuals with diabetes.

RESEARCH DESIGN AND METHODS—A random sample of diabetic patients receiving care in the Department of Veterans Affairs health care system were surveyed during January-March 2000. The association between aspirin counseling, aspirin use, and reported coronary vascular disease (CVD) and classical CVD risk factors were examined using logistic regression. The effect of increasing aspirin use on risk of myocardial infarction (MI) and cardiovascular mortality was demonstrated by simulation.

RESULTS—Seventy-one percent of respondents reported being counseled about aspirin use, and 66% were taking daily aspirin. Individuals with known CVD were more likely to be counseled (odds ratio [OR] 4.9, 95% CI 2.9–8.1) and to use aspirin (2.1, 1.2–3.7). The factor most strongly associated with aspirin use was having been counseled about aspirin therapy by a doctor. We estimate that for this population, increasing daily aspirin use to 90% could prevent an additional 11,000 MIs and potentially save >8,000 lives.

CONCLUSIONS—Compared with previous reports, a substantial proportion of these diabetic patients have been counseled about and use aspirin. Most clinicians recognize aspirin as an important treatment for patients with preexisting coronary disease. However, since diabetes is now considered a CVD equivalent, it is imperative that clinicians include counseling about aspirin therapy as a care priority for all their diabetic patients, as this simple intervention may prevent many cardiovascular events and deaths.

Abbreviations: CVD, coronary vascular disease • DQIP, Diabetes Quality Improvement Project • MI, myocardial infarction • OR, odds ratio • VA, Veterans Affairs • VISN, veterans integrated service network


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
J. C. O'Connor, C. L. Sherry, C. B. Guest, and G. G. Freund
Type 2 Diabetes Impairs Insulin Receptor Substrate-2-Mediated Phosphatidylinositol 3-Kinase Activity in Primary Macrophages to Induce a State of Cytokine Resistance to IL-4 in Association with Overexpression of Suppressor of Cytokine Signaling-3
J. Immunol., June 1, 2007; 178(11): 6886 - 6893.
[Abstract] [Full Text] [PDF]


Home page
The Diabetes EducatorHome page
T. S. Tang, M. L. Gillard, M. M. Funnell, R. Nwankwo, E. Parker, D. Spurlock, and R. M. Anderson
Developing a New Generation of Ongoing Diabetes Self-management Support Interventions: A Preliminary Report
The Diabetes Educator, January 1, 2005; 31(1): 91 - 97.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
S. D. Persell and D. W. Baker
Aspirin Use Among Adults With Diabetes: Recent Trends and Emerging Sex Disparities
Arch Intern Med, December 13, 2004; 164(22): 2492 - 2499.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
V. M. Montori, S. C. Bryant, A. M. O'Connor, N. W. Jorgensen, E. E. Walsh, and S. A. Smith
Decisional Attributes of Patients With Diabetes: The aspirin choice
Diabetes Care, October 1, 2003; 26(10): 2804 - 2809.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. Heisler, D. M. Smith, R. A. Hayward, S. L. Krein, and E. A. Kerr
How Well Do Patients' Assessments of Their Diabetes Self-Management Correlate With Actual Glycemic Control and Receipt of Recommended Diabetes Services?
Diabetes Care, March 1, 2003; 26(3): 738 - 743.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2002 by the American Diabetes Association.